SLNSW-A phase I study to determine the maximum tolerate...-TN_cdi_proquest_journals_1727156550

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer

Full title: A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer

Author/creator: Wisinski, Kari B, Ledesma, Wendy M, Kolesar, Jill, Wilding, George, Liu, Glenn, Douglas, Jeffrey, Traynor, Anne M, Albertini, Mark, Mulkerin, Daniel, Bailey, Howard H.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_1727156550

Language: English

Formats: Articles

Publishers: London, England: SAGE Publications

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1727156550

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer

    Record identifier

    TN_cdi_proquest_journals_1727156550

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1727156550

    Share

    A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1727156550

    A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer

    Full title

    A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer

    Author / Creator

    Wisinski, Kari B ; Ledesma, Wendy M ; Kolesar, Jill ; Wilding, George ; Liu, Glenn ; Douglas, Jeffrey ; Traynor, Anne M ; Albertini, Mark ; Mulkerin, Daniel ; Bailey, Howard H

    Publisher

    London, England: SAGE Publications

    Journal title

    Journal of oncology pharmacy practice, 2015, Vol.21 (6), p.416-424

    Record Identifier

    TN_cdi_proquest_journals_1727156550

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Aged Aged, 80 and over Alkaline Phosphatase - blood Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Calcium - blood Cancer Dose-Response Relationship, Drug Ergocalciferols - administration & dosage Ergocalciferols - adverse effects Ergocalciferols - therapeutic use Female Humans Hypercalcemia - chemically induced Hypercalciuria - chemically induced Male Maximum Tolerated Dose Middle Aged Muscle Fatigue Neoplasms - drug therapy Osteocalcin - blood Parathyroid Hormone - blood phase I Studies Toxins Urinary Tract Infections - complications Vitamin D

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_1727156550

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1727156550

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections